Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of “Hold” by Brokerages

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has been assigned an average recommendation of “Hold” from the five research firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $3.67.

LXRX has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Piper Sandler lowered their price target on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Friday, March 28th. Leerink Partnrs cut Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Finally, StockNews.com assumed coverage on shares of Lexicon Pharmaceuticals in a report on Monday, April 21st. They issued a “sell” rating on the stock.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ:LXRX opened at $0.68 on Friday. The company has a market cap of $167.59 million, a P/E ratio of -0.91 and a beta of 1.02. The business has a fifty day simple moving average of $0.49 and a 200-day simple moving average of $0.80. Lexicon Pharmaceuticals has a 52 week low of $0.28 and a 52 week high of $2.45. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.02. The company had revenue of $26.55 million during the quarter, compared to analysts’ expectations of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. Equities research analysts forecast that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Bayesian Capital Management LP acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $31,000. RPO LLC acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at $33,000. Renaissance Technologies LLC acquired a new stake in Lexicon Pharmaceuticals during the 4th quarter valued at $38,000. Straight Path Wealth Management purchased a new stake in Lexicon Pharmaceuticals during the 1st quarter worth $29,000. Finally, Arizona State Retirement System boosted its position in Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 16,136 shares during the last quarter. 74.70% of the stock is currently owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.